Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 2/2014

01.08.2014

Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis

verfasst von: Minh Phan, Sonia John, Ana I. Casanegra, Suman Rathbun, Aaron Mansfield, Julie A. Stoner, Alfonso J. Tafur

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Venous thromboembolism (VTE) is a leading cause of death among outpatient chemotherapy patients. However the VTE preventive measures for outpatients are not widely advocated. We did a meta-analysis to evaluate the outpatient VTE prevention’s effectiveness and safety. We searched electronic databases until the end of December 2012 and reviewed the abstracts and manuscripts following the PRISMA guidelines. Occurrence of first VTE event was the efficacy outcome. The safety end point was major bleeding. We calculated Q statistic and a homogeneity formal test. The odds ratio (OR) estimates were pooled by using the Mantel–Haenszel fixed-effects method in the absence of heterogeneity. Data were analyzed using the R META package). We identified 1,485 articles and reviewed 37 articles based on initial screening. The number of patients included in 11 selected trials was 7,805. The odds of VTE was lower in the prophylaxis group (OR 0.56; 95 % CI 0.45–0.71) and improved when heparin-based prevention was analyzed (OR 0.53; 95 % CI 0.41–0.70). We found strong prevention among patients with lung cancer (OR 0.46; 95 % CI 0.29–0.74) and pancreatic cancer (OR 0.33; 95 % CI 0.16–0.67). Major bleeding events were frequent in the intervention group (OR 1.65; 95 % CI 1.12–2.44). Thromboprophylaxis reduced VTE episodes. The VTE events were reduced by 47 % in heparin-based prophylaxis trials compared to placebo. The patients receiving heparin-based prophylaxis had a 60 % increase in bleeding events. Improving risk stratification tools to personalize prevention strategies may enhance the VTE prevention applicability in cancer patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Int Med 160(6):809–815CrossRef Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Int Med 160(6):809–815CrossRef
2.
Zurück zum Zitat Roger VL et al (2012) Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation 125(1):e2–e220PubMedCrossRef Roger VL et al (2012) Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation 125(1):e2–e220PubMedCrossRef
3.
Zurück zum Zitat Khorana AA, Francis CW, Culakova E, Kudere NM, Lyman GH (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5:632–634PubMedCrossRef Khorana AA, Francis CW, Culakova E, Kudere NM, Lyman GH (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5:632–634PubMedCrossRef
4.
Zurück zum Zitat Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343(25):1846–1850PubMedCrossRef Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343(25):1846–1850PubMedCrossRef
5.
Zurück zum Zitat Dobesh PP (2009) Economic Burden of Venous Thromboembolism in Hospitalized Patients. Pharmacotherapy 29(8):943–953PubMedCrossRef Dobesh PP (2009) Economic Burden of Venous Thromboembolism in Hospitalized Patients. Pharmacotherapy 29(8):943–953PubMedCrossRef
6.
Zurück zum Zitat Agnelli G et al (2012) Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 366(7):601–609PubMedCrossRef Agnelli G et al (2012) Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 366(7):601–609PubMedCrossRef
7.
Zurück zum Zitat Heit JA et al (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160(6):809–815PubMedCrossRef Heit JA et al (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160(6):809–815PubMedCrossRef
8.
Zurück zum Zitat Heit JA et al (2000) Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 160(6):761–768PubMedCrossRef Heit JA et al (2000) Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 160(6):761–768PubMedCrossRef
9.
Zurück zum Zitat Streiff M et al (2013) Venous thromboembolic disease. National Comprenesive Cancer Network, Washington Streiff M et al (2013) Venous thromboembolic disease. National Comprenesive Cancer Network, Washington
10.
Zurück zum Zitat Lyman GH et al (2007) American society of clinical oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490–5505PubMedCrossRef Lyman GH et al (2007) American society of clinical oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490–5505PubMedCrossRef
11.
Zurück zum Zitat Mandala M, Falanga A, Roila F (2011) Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines. Ann Oncol 22(6):vi85–vi92PubMed Mandala M, Falanga A, Roila F (2011) Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines. Ann Oncol 22(6):vi85–vi92PubMed
12.
Zurück zum Zitat Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H (2012) Schulman prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2):e195S–e226SPubMedCentralPubMed Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H (2012) Schulman prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2):e195S–e226SPubMedCentralPubMed
13.
Zurück zum Zitat Khorana AA et al (2012) Preventing VTE in outpatients with cancer. Chest 142(1):266–267CrossRef Khorana AA et al (2012) Preventing VTE in outpatients with cancer. Chest 142(1):266–267CrossRef
14.
Zurück zum Zitat Liberati A et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700PubMedCentralPubMedCrossRef Liberati A et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Egger M (2001) Systematic reviews in health care. In: Altman D (ed) Meta-analysis in Contex. BMJ Books, London Egger M (2001) Systematic reviews in health care. In: Altman D (ed) Meta-analysis in Contex. BMJ Books, London
17.
Zurück zum Zitat Huedo-Medina TB et al (2006) Assessing heterogeneity in meta-analysis: q statistic or I2 index? Psychol Methods 11(2):193–206PubMedCrossRef Huedo-Medina TB et al (2006) Assessing heterogeneity in meta-analysis: q statistic or I2 index? Psychol Methods 11(2):193–206PubMedCrossRef
19.
Zurück zum Zitat Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719–748PubMed Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719–748PubMed
20.
Zurück zum Zitat Young AM et al (2009) Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet 373(9663):567–574PubMedCrossRef Young AM et al (2009) Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet 373(9663):567–574PubMedCrossRef
21.
Zurück zum Zitat Haas SK et al (2012) Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost 18(2):159–165PubMedCrossRef Haas SK et al (2012) Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost 18(2):159–165PubMedCrossRef
22.
Zurück zum Zitat Levine M et al (1994) Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343(8902):886–889PubMedCrossRef Levine M et al (1994) Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343(8902):886–889PubMedCrossRef
23.
Zurück zum Zitat Kakkar AK et al (2004) Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22(10):1944–1948PubMedCrossRef Kakkar AK et al (2004) Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22(10):1944–1948PubMedCrossRef
24.
Zurück zum Zitat Perry JR et al (2010) PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 8(9):1959–1965PubMedCrossRef Perry JR et al (2010) PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 8(9):1959–1965PubMedCrossRef
25.
Zurück zum Zitat Maraveyas A et al (2012) Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 48(9):1283–1292PubMedCrossRef Maraveyas A et al (2012) Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 48(9):1283–1292PubMedCrossRef
26.
Zurück zum Zitat Klerk CPW et al (2005) The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23(10):2130–2135PubMedCrossRef Klerk CPW et al (2005) The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23(10):2130–2135PubMedCrossRef
27.
Zurück zum Zitat van Doormaal FF et al (2011) Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol 29(15):2071–2076PubMedCrossRef van Doormaal FF et al (2011) Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol 29(15):2071–2076PubMedCrossRef
28.
Zurück zum Zitat Agnelli G et al (2009) Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncology 10(10):943–949PubMedCrossRef Agnelli G et al (2009) Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncology 10(10):943–949PubMedCrossRef
29.
Zurück zum Zitat Di Nisio M et al (2012) Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev 15(2):CD008500 Di Nisio M et al (2012) Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev 15(2):CD008500
30.
Zurück zum Zitat Altinbas M et al (2004) A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2(8):1266–1271PubMedCrossRef Altinbas M et al (2004) A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2(8):1266–1271PubMedCrossRef
31.
Zurück zum Zitat Sideras K et al (2006) Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 81(6):758–767PubMedCrossRef Sideras K et al (2006) Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 81(6):758–767PubMedCrossRef
32.
Zurück zum Zitat Akl EA et al (2011) Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 15(6):CD006650 Akl EA et al (2011) Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 15(6):CD006650
33.
Zurück zum Zitat Verso M, Gussoni G, Agnelli G (2010) Prevention of venous thromboembolism in patients with advanced lung cancer receiving chemotherapy: a combined analysis of the PROTECHT and TOPIC-2 studies. J Thromb Haemost 8(7):1649–1651PubMedCrossRef Verso M, Gussoni G, Agnelli G (2010) Prevention of venous thromboembolism in patients with advanced lung cancer receiving chemotherapy: a combined analysis of the PROTECHT and TOPIC-2 studies. J Thromb Haemost 8(7):1649–1651PubMedCrossRef
34.
Zurück zum Zitat Pishko AM, Smith KJ, Ragni MV (2012) Anticoagulation in ambulatory cancer patients with no indication for prophylactic or therapeutic anticoagulation: a cost-effectiveness analysis from a U.S. perspective. Thromb Haemost 108(2):303–310PubMedCrossRef Pishko AM, Smith KJ, Ragni MV (2012) Anticoagulation in ambulatory cancer patients with no indication for prophylactic or therapeutic anticoagulation: a cost-effectiveness analysis from a U.S. perspective. Thromb Haemost 108(2):303–310PubMedCrossRef
35.
Zurück zum Zitat Carrier M et al (2012) Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis. J Thromb Haemost 10(12):2599–2601PubMedCrossRef Carrier M et al (2012) Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis. J Thromb Haemost 10(12):2599–2601PubMedCrossRef
36.
Zurück zum Zitat Debourdeau P et al (2013) International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost 11(1):71–80PubMedCrossRef Debourdeau P et al (2013) International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost 11(1):71–80PubMedCrossRef
37.
Zurück zum Zitat Verso M, Agnelli G (2003) Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 21(19):3665–3675PubMedCrossRef Verso M, Agnelli G (2003) Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 21(19):3665–3675PubMedCrossRef
38.
Zurück zum Zitat Lee AY et al (2006) Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol 24(9):1404–1408PubMedCrossRef Lee AY et al (2006) Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol 24(9):1404–1408PubMedCrossRef
39.
Zurück zum Zitat Evans RS et al (2010) Risk of symptomatic DVT associated with peripherally inserted central catheters. Chest 138(4):803–810PubMedCrossRef Evans RS et al (2010) Risk of symptomatic DVT associated with peripherally inserted central catheters. Chest 138(4):803–810PubMedCrossRef
40.
Zurück zum Zitat Levine MN et al (2012) A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost 10(5):807–814PubMedCrossRef Levine MN et al (2012) A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost 10(5):807–814PubMedCrossRef
41.
Zurück zum Zitat Verso M et al (2012) A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the protecht score. Intern Emerg Med 7(3):291–292PubMedCrossRef Verso M et al (2012) A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the protecht score. Intern Emerg Med 7(3):291–292PubMedCrossRef
42.
Zurück zum Zitat Barni S et al (2011) Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med 9:179PubMedCentralPubMedCrossRef Barni S et al (2011) Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med 9:179PubMedCentralPubMedCrossRef
43.
Zurück zum Zitat Ay C et al (2008) High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 112(7):2703–2708PubMedCrossRef Ay C et al (2008) High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 112(7):2703–2708PubMedCrossRef
44.
45.
46.
Zurück zum Zitat Date K et al (2013) Tumour and microparticle tissue factor expression and cancer thrombosis. Thromb Res 131(2):109–115PubMedCrossRef Date K et al (2013) Tumour and microparticle tissue factor expression and cancer thrombosis. Thromb Res 131(2):109–115PubMedCrossRef
47.
Zurück zum Zitat Zwicker JI et al (2013) Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). Br J Haematol 160(4):530–537PubMedCentralPubMedCrossRef Zwicker JI et al (2013) Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). Br J Haematol 160(4):530–537PubMedCentralPubMedCrossRef
48.
Zurück zum Zitat Stender MT et al (2009) Preoperative plasma D-dimer is a predictor of postoperative deep venous thrombosis in colorectal cancer patients: a clinical, prospective cohort study with one-year follow-up. Dis Colon Rectum 52(3):446–451PubMedCrossRef Stender MT et al (2009) Preoperative plasma D-dimer is a predictor of postoperative deep venous thrombosis in colorectal cancer patients: a clinical, prospective cohort study with one-year follow-up. Dis Colon Rectum 52(3):446–451PubMedCrossRef
49.
Zurück zum Zitat Zwicker JI et al (2009) Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 15(22):6830–6840PubMedCentralPubMedCrossRef Zwicker JI et al (2009) Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 15(22):6830–6840PubMedCentralPubMedCrossRef
Metadaten
Titel
Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis
verfasst von
Minh Phan
Sonia John
Ana I. Casanegra
Suman Rathbun
Aaron Mansfield
Julie A. Stoner
Alfonso J. Tafur
Publikationsdatum
01.08.2014
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 2/2014
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-013-1014-9

Weitere Artikel der Ausgabe 2/2014

Journal of Thrombosis and Thrombolysis 2/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.